Corxel Pharmaceuticals’ oral GLP-1 agonist CX11 achieved up to 11.5% weight loss in a U.S. Phase 2 obesity trial, supporting advancement into global Phase 3 development following positive China Phase 3 results.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
Corxel Pharmaceuticals has announced positive top-line results from a U.S. Phase 2 trial of CX11, an investigational oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), in adults with obesity or overweight.
The study met its primary efficacy endpoints, with participants achieving up to 11.5% weight loss at 36 weeks, supporting the company’s plans to advance CX11 into global Phase 3 development.
The findings build on positive Phase 3 obesity results recently reported in China by Corxel’s partner, Vincentage Pharma, reinforcing confidence in the candidate’s efficacy and safety profile across clinical programs.
Up to 11.5% Weight Loss at 36 Weeks
The randomized, double-blind, placebo-controlled Phase 2 study (NCT07011797) enrolled 246 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI 27–29.9 kg/m²) with at least one weight-related comorbidity. Participants were randomized equally to receive CX11 120 mg, CX11 160 mg, CX11 200 mg with slow titration, CX11 200 mg with fast titration, or placebo once daily for 36 weeks.
At Week 36, CX11 achieved up to 11.5% weight loss among obesity patients. Weight reduction continued at a consistent rate throughout treatment, with no evidence of a slowing trajectory or plateau effect.
Favorable Safety and Tolerability
CX11 demonstrated a favorable safety profile during the 36-week treatment period. The most commonly reported adverse events were gastrointestinal and generally mild to moderate in severity.
Nausea occurred in 33% to 34% of participants, vomiting in 12% to 16%, diarrhea in 4% to 12%, and constipation in 2% to 12% across treatment groups. No severe cases of nausea, vomiting, diarrhea, or constipation were reported. Most gastrointestinal adverse events occurred during dose escalation and gradually subsided during the maintenance phase. The treatment discontinuation rate due to gastrointestinal adverse events was 5.0%.
No hepatic safety signal was observed in the study. Corxel noted that more than 1,500 participants have received CX11 across clinical studies to date, with no hepatic safety concerns identified.
Advancing Toward Global Development
Corxel acquired global rights outside China to develop and commercialize CX11 from Vincentage Pharma in December 2024. Following the positive U.S. Phase 2 and China Phase 3 results, the company plans to initiate pivotal global Phase 3 studies.
CX11 is being developed as a once-daily oral GLP-1 receptor agonist for obesity, overweight, and other cardiometabolic conditions. The company believes an oral option could help address some of the barriers associated with current injectable GLP-1 therapies, including treatment convenience and long-term adherence.
Commenting on the results, Bo Liang, MD, PhD, Chief Medical Officer of Corxel, said the U.S. Phase 2 findings are consistent with the competitive profile established in the China Phase 3 program and support the potential of CX11 as an effective, well-tolerated treatment with dosing flexibility. He added that the company looks forward to advancing the candidate into pivotal global Phase 3 studies.
What This Means for Patients
For patients living with obesity or overweight-related health conditions, CX11 may provide a convenient oral alternative to injectable GLP-1 therapies. The study demonstrated meaningful weight loss of up to 11.5% while maintaining favorable tolerability, a low discontinuation rate, and no identified liver safety concerns. As many patients struggle with injections, dose titration, or treatment adherence, a once-daily oral option could improve long-term treatment acceptance and accessibility. If future Phase 3 studies confirm these findings, CX11 has the potential to expand treatment choices and help more patients achieve sustainable weight management and improved cardiometabolic health.
Reference
About the Writer
Meghana Jinka (LinkedIn) is a Pharm.D graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.